CCNE2-related Nephropathy Drug Targets (G9134)

CCNE2-related Nephropathy Drug Targets

The carbohydrate-rich nephropathy (CCNE2-related nephropathy), also known as Jasmeet-Verma nephropathy, is a type of nephropathy that is characterized by the progressive damage of the glomeruli and interstitial tissues, leading to the loss of urine. This condition is a major source of morbidity and mortality, especially in individuals with a history of diabetes. Currently, there are limited treatment options available for CCNE2-related nephropathy, and there is a high need for new and effective therapies.

The CCNE2 gene

The CCNE2 gene is a member of the hexokinase gene family, which is responsible for the biosynthesis of glucose and other simple sugars. The CCNE2 gene encodes a protein that is involved in the uptake and storage of glucose in the renal collecting tubules. The primary function of the CCNE2 protein is to transport glucose from the renal interstitial space to the plasma.

However, research has shown that in individuals with CCNE2-related nephropathy, the CCNE2 protein is expressed at higher levels in the urine compared to the plasma. This suggests that the CCNE2 protein may play a role in the development and progression of this condition.

Drug targets for CCNE2-related nephropathy

The high expression of the CCNE2 protein in individuals with CCNE2-related nephropathy makes it an attractive drug target. There are several potential drug candidates that have been shown to interact with the CCNE2 protein, with a focus on inhibiting its activity in nephropathy.

One potential drug target for CCNE2-related nephropathy is the angiotensin-converting enzyme (ACE) inhibitor, which is a commonly used treatment for hypertension. ACE inhibitors have been shown to reduce inflammation and fibrosis in individuals with nephropathy, including CCNE2-related nephropathy.

Another potential drug target for CCNE2-related nephropathy is the sodium-glucose cotransporter (SGLT2), which is responsible for reabsorbing glucose from the urine. SGLT2 inhibitors have been shown to improve renal function in individuals with nephropathy, including CCNE2-related nephropathy.

In addition to these drug targets, there is also interest in targeting the CCNE2 gene itself. Researchers have shown that inhibiting the activity of the CCNE2 protein using small interfering RNA (siRNA) can reduce inflammation and fibrosis in individuals with CCNE2-related nephropathy.

Conclusion

The CCNE2 gene is involved in the uptake and storage of glucose in the renal collecting tubules, and its high expression in individuals with CCNE2-related nephropathy suggests that it plays a role in the development and progression of this condition. Drug targets such as the angiotensin -converting enzyme (ACE) inhibitor and the sodium-glucose cotransporter (SGLT2) have been shown to be effective in treating CCNE2-related nephropathy, and there is also interest in targeting the CCNE2 protein itself. Further research is needed to determine the most effective and safe therapies for CCNE2-related nephropathy.

Protein Name: Cyclin E2

Functions: Essential for the control of the cell cycle at the late G1 and early S phase

The "CCNE2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCNE2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C